S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
This Skill Could Change The Way You Trade! (Ad)pixel
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
This Skill Could Change The Way You Trade! (Ad)pixel
UK arrests wealthy Russian as police target Putin enablers
Moldova signs new energy deal that could ease blackout risk
The single greatest medical breakthrough of all time? (Ad)
Tennessee roads plan mulls toll lanes, electric car fee hike
OPEC+ oil producers face uncertainty over Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
This Skill Could Change The Way You Trade! (Ad)pixel
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
This Skill Could Change The Way You Trade! (Ad)pixel
UK arrests wealthy Russian as police target Putin enablers
Moldova signs new energy deal that could ease blackout risk
The single greatest medical breakthrough of all time? (Ad)
Tennessee roads plan mulls toll lanes, electric car fee hike
OPEC+ oil producers face uncertainty over Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
This Skill Could Change The Way You Trade! (Ad)pixel
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
This Skill Could Change The Way You Trade! (Ad)pixel
UK arrests wealthy Russian as police target Putin enablers
Moldova signs new energy deal that could ease blackout risk
The single greatest medical breakthrough of all time? (Ad)
Tennessee roads plan mulls toll lanes, electric car fee hike
OPEC+ oil producers face uncertainty over Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
This Skill Could Change The Way You Trade! (Ad)pixel
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
This Skill Could Change The Way You Trade! (Ad)pixel
UK arrests wealthy Russian as police target Putin enablers
Moldova signs new energy deal that could ease blackout risk
The single greatest medical breakthrough of all time? (Ad)
Tennessee roads plan mulls toll lanes, electric car fee hike
OPEC+ oil producers face uncertainty over Russian sanctions
NASDAQ:CYTX

Cytori Therapeutics - CYTX Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$0.38
$0.42
50-Day Range
$0.20
$0.21
52-Week Range
$0.20
$0.75
Volume
275,594 shs
Average Volume
915,302 shs
Market Capitalization
$9.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
CYTX stock logo

About Cytori Therapeutics (NASDAQ:CYTX) Stock

Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.

Receive CYTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYTX Stock News Headlines

8 Stocks Under $10 Ripping Higher
Phase 3
Insider Activity CYTORI THERAPEUTICS, INC.
News for Cytori Therapeutics Inc Registered Shs
Plus Therapeutics Inc
Cytori Therapeutics (CYTX) - Options Chain
Plus Therapeutics to reverse split 1:50
Cytori to become Plus Therapeutics
Cytori Will Become Plus Therapeutics, Inc.
Cytori to Present New Strategic Direction
Cytori Reports Q1 2019 Business and Financial Results
Japan Cell Therapy Transaction Yields $3MM
See More Headlines

Receive CYTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYTX Company Calendar

Last Earnings
5/14/2019
Today
12/04/2022

Industry, Sector and Symbol

Industry
Surgical & Medical Instruments
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CYTX
CUSIP
23283K10
Fax
N/A
Employees
37
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+2,068.7%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-12,630,000.00
Net Margins
-242.60%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.67 million
Book Value
$0.35 per share

Miscellaneous

Free Float
N/A
Market Cap
$9.20 million
Optionable
Optionable
Beta
1.96

Key Executives

  • Marc H. Hedrick
    President, Chief Executive Officer & Director
  • Gary S. Titus
    Chief Financial Officer
  • Mark T. Marino
    Chief Medical Officer & Senior Vice President
  • John K. Fraser
    Chief Scientist
  • Russ Havranek
    VP-Global Marketing & Business Development













CYTX Stock - Frequently Asked Questions

What is Cytori Therapeutics' stock price forecast for 2023?

0 Wall Street analysts have issued 12 month target prices for Cytori Therapeutics' shares. Their CYTX share price forecasts range from $9.00 to $9.00. On average, they expect the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 2,068.7% from the stock's current price.
View analysts price targets for CYTX
or view top-rated stocks among Wall Street analysts.

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) announced its earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.02. The biotechnology company earned $0.70 million during the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative trailing twelve-month return on equity of 272.70%.

When did Cytori Therapeutics' stock split?

Cytori Therapeutics shares reverse split on the morning of Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cytori Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), Exelixis (EXEL), Athersys (ATHX), BCE (BCE), Celldex Therapeutics (CLDX), Synergy Pharmaceuticals (SGYP) and Novavax (NVAX).

What is Cytori Therapeutics' stock symbol?

Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."

What is Cytori Therapeutics' stock price today?

One share of CYTX stock can currently be purchased for approximately $0.42.

How much money does Cytori Therapeutics make?

Cytori Therapeutics (NASDAQ:CYTX) has a market capitalization of $9.20 million and generates $3.67 million in revenue each year.

How can I contact Cytori Therapeutics?

Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The official website for the company is www.cytori.com. The biotechnology company can be reached via phone at 858-458-0900 or via email at ir@cytori.com.

This page (NASDAQ:CYTX) was last updated on 12/4/2022 by MarketBeat.com Staff